ganciclovir: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ganciclovir: clinical details
Prescribing considerations
- Confirm acute herpetic keratitis; efficacy has not been demonstrated for other viral keratoconjunctivitis.
- The product is not indicated for CMV retinitis.
- Use under 18 years is not recommended because specific studies are unavailable.
- Consider pregnancy, breastfeeding, reproductive counselling, concurrent topical treatments and potentially toxic systemic medicines.
- Benzalkonium chloride can irritate dry or damaged corneas and can be absorbed by soft contact lenses.
Contraindications and cautions
- Hypersensitivity to ganciclovir, aciclovir or any excipient.
- Pregnancy or breastfeeding: not recommended unless no suitable alternative is available.
Monitoring
- Assess corneal healing, visual symptoms and ocular tolerability.
- Urgently reassess worsening pain, redness, photophobia or visual change.
- No routine systemic laboratory monitoring is specified for the eye gel; consider individual risks with interacting systemic medicines.
Clinical pharmacology
Ganciclovir is phosphorylated predominantly in virus-infected cells. Its triphosphate metabolite competitively inhibits viral DNA polymerase and limits DNA-chain elongation. Systemic exposure after ocular administration is very low.
Formulation and product differences
- The selected product is a multidose aqueous eye gel containing benzalkonium chloride.
- It is for ocular use and is not interchangeable with intravenous ganciclovir products.
- The tube has no special storage requirement and should be discarded four weeks after opening.
ganciclovir interactions
Absorption from the eye is low, but clinically important systemic interactions cannot be completely excluded.
Other topical eye treatments
Separate administration by at least 15 minutes and apply ganciclovir gel last.
Probenecid
May reduce ganciclovir clearance; the prescriber should review combined use.
Zidovudine or other medicines that suppress bone marrow
Combined use may increase blood-cell toxicity, although exposure from the eye gel is small.
Imipenem with cilastatin
Seizures have been reported with systemic ganciclovir, so combined use requires prescriber review.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.